Allergan is buying Repros Therapeutics for $0.67 per share. The deal is expected to close in the first quarter of 2018.
Radius Health Delays Osteoporosis Drug Application in the U.S. to Avoid Rush, Respect Staffers’ Holidays
Analysts, Bone Fractures, Breast Cancer, Clinical Trials, Data, FDA, FDA/Regulatory, Fractures, Health, MAA, Marketing Authorization Application (MAA), NDA, NDA/MAA, New Drug Application (NDA), New Drug Applications, Osteoporosis, R&D, Stocks, Stocks, Vasomotor SymptomsNovember 18, 2015By Mark Terry, BioSpace.com Breaking News Staff Waltham, Mass.-based Radius Health, Inc. (RDUS), announced yesterday that it has sent a Marketing Authorization Application (MAA) to European regulatory agencies for its abaloparatide-SC for postmenopausal osteoporosis. At the same time, the company indicated that it is delaying its New Drug Application (NDA) to the […]
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for grazoprevir/elbasvir (100mg/50mg), an investigational, once-daily, single-tablet combination therapy for the treatment of adult patients with chronic hepatitis C (HCV) genotypes (GT) 1, 3, 4 or […]